GlaukosGKOS -1.52%79 EV-to-EBIT is -46.31 as of Jul. 10, 2026. GuruFocus rates GKOS with a GF Score™ of 79/100 and a GF Value™ of $136.35 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 464 Medical Devices & Instruments companies, Glaukos ranks worse than 215517.03% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Glaukos's Enterprise Value is $8,796.2 Mil.
Glaukos's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $-189.9 Mil. Therefore, Glaukos's EV-to-EBIT for today is -46.31.
The historical rank and industry rank for Glaukos's EV-to-EBIT or its related term are showing as below:
GKOS'
s EV-to-EBIT Range Over the Past 10 Years
Min: -3262.61 Med: -43.52 Max: 1645.96
Current: -46.31
During the past 13 years, the highest EV-to-EBIT of Glaukos was 1645.96. The lowest was -3262.61. And the median was -43.52.
GKOS's EV-to-EBIT is ranked worse than 100% of 464
companies
in the Medical Devices & Instruments industry
Industry Median: 18.34
vs GKOS: -46.31
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Glaukos's Enterprise Value for the quarter that ended in Mar. 2026 was $6,109.3 Mil.
Glaukos's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-189.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Glaukos EV-to-EBIT Related Terms
Glaukos EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Glaukos's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Glaukos's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Glaukos EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Glaukos's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Glaukos's EV-to-EBIT falls into.
Glaukos's current Enterprise Value is $8,796.2 Mil.
Glaukos's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-189.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Glaukos (GKOS) has a EV-to-EBIT of -46.31 as of Jul. 10, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Glaukos and its competitors. According to the industry distribution chart, Glaukos ranks #999999 out of 464 companies in the Medical Devices & Instruments industry.
Is Glaukos' EV-to-EBIT too high?
Glaukos' current EV-to-EBIT is -46.31. Based on the distribution chart, Glaukos ranks #999999 out of 464 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Glaukos has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Glaukos' EV-to-EBIT compare to BIO and BRKR?
According to the Medical Devices & Instruments industry distribution chart, Glaukos ranks #999999 out of 464 companies for EV-to-EBIT. This places Glaukos in the lower half of its industry. The industry median EV-to-EBIT is 18.34. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.34, based on 464 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Glaukos and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Glaukos's current EV-to-EBIT is -46.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glaukos stock overvalued right now?
Based on GuruFocus' analysis, Glaukos (GKOS) is currently considered Modestly Overvalued. The stock's GF Value™ is $136.35, compared to a current price of $152.72 — trading 12% above its estimated fair value. The current EV-to-EBIT is -46.31. Glaukos' overall GF Score™ is 79/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Glaukos (GKOS), the current EV-to-EBIT is -46.31 as of Jul. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Glaukos (GKOS) Overvalued in 2026?
Based on GuruFocus' analysis, Glaukos stock appears to be overvalued.
The current stock price of $152.72 is trading 12% above its estimated GF Value™ of $136.35.
GuruFocus considers Glaukos to be Modestly Overvalued.
Key valuation signals for GKOS:
EV-to-EBIT: -46.31
GF Value™: $136.35 vs. price of $152.72 (12% above fair value)
No single metric tells the full story. See the GKOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
79GF Score
Get the complete analysis for GKOS
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GKOS has been successfully added to your 
